An Eye for the Future: Does an Interdisciplinary View Help Improve Discounting Approaches for Curative Gene Therapies?

Speaker(s)

Moderator: Simon Brassel, MSc, Dipl.-Ing, Office of Health Economics, London, UK
Speakers: Avril Daly, BSc, Retina International, Zürich, Switzerland; Nicola Clair Clair Trevor, MSc, Janssen, High Wycombe, UK; Grace Hampson, MSc, The Office of Health Economics, London, London, UK; Mohamed El Alili, PhD, National Health Care Institute, Diemen, Netherlands

Presentation Documents

How much should we invest today to unlock health and well-being in the future? Current methodologies to answer this question require discounting future costs and benefits within an economic evaluation reflecting societal preferences for immediate impact. Yet, technological progress enables the generation of benefits ever longer into the future, amplifying the impact of most discounting practices on today's decision-making. Within health, this issue manifests itself notably in preventative interventions, including advanced therapy medicinal products (gene, cell and regenerative therapies) with long-term benefits. But other fields adjacent to health, most prominently climate change, experience the same issue: A long time lag between the costs of actions taken today and the related benefits in the future - be it health gained or tons of carbon saved - poses challenges to current investment decisions.

Sponsored by Office of Health Economics

Code

236

Topic

Health Technology Assessment